Chemed Q1 revenue up 5.6% to $560M; adjusted EPS $4.82 (+0.6%)

CHEMED CORP

2023-Q1 EPS reported $3.58 revenue$560,157,000

GAAP diluted EPS $3.58; adjusted diluted EPS $4.82, up 0.6% YoY.
VITAS net patient revenue $310M (+3.8%), ADC 17,830 (+3.0%), but adjusted EBITDA margin fell 234 bps to 15.1% due to sequestration and hiring.
Roto-Rooter revenue $250M (+7.9%), adjusted EBITDA $71.8M (+9.0%), margin 28.8% (+29 bps).
Cash $58.1M, debt $21.3M; $405M undrawn revolver.
Management will provide updated 2023 guidance in June 2023 earnings release.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CHEMED CORP reported first quarter ended March 31, 2023 results: revenue $560 million, EPS $3.58.

Period: first quarter ended March 31, 2023
Revenue: $560 million
EPS: $3.58
Result: reported results

Exact text from the filing

Chemed Corporation (Chemed) (NYSE: CHE ), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its first quarter ended March 31, 2023, versus the comparable prior-year period, as follows: Consolidated operating results: · Revenue increased 5.6% to $560 million · GAAP Diluted Earnings-per-Share (EPS) of $3.58 · Adjusted Diluted EPS of $4.82

View on SEC.gov

Browse all earnings releases →

CHEMED CORP filing history →

Source: SEC EDGAR

accession 0001562762-23-000174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.